Key result
Angiotensin II facilitated stimulation-induced vasoconstrictor responses, but this enhancing effect was significantly decreased in mesenteric arteries from rabbits with chronic heart failure (P<0.05).
Why the study?
Does Angiotensin II facilitate noradrenergic neurotransmission differently in isolated mesenteric arteries of rabbits with chronic heart failure compared to controls?
Does Angiotensin II facilitate noradrenergic neurotransmission differently in isolated mesenteric arteries of rabbits with chronic heart failure compared to controls?
The facilitatory effect of Angiotensin II on sympathetic neurotransmission via prejunctional AT1 receptors is decreased in mesenteric arteries of rabbits with chronic heart failure.
Reduced Ang II facilitation in CHF arteries is hypothesis-generating; leaves open translation to human sympathetic control.
Both in human and in experimental heart failure (HF), the renin-angiotensin system and the sympathetic nervous system are activated. In a previous study a facilitatory action of angiotensin II (Ang II) was shown in the rabbit mesenteric artery, which was mediated via prejunctionally located Ang II type 1 (AT ) receptors. Very little is known about the effects of Ang II on sympathetic neurotransmission at the peripheral level in congestive heart failure (CFH). Accordingly, in the isolated mesenteric arteries obtained from rabbits with experimentally induced CHF, as well as in age-matched control rabbits, the effect of Ang II on contractions provoked by electrical field stimulation was investigated in the presence and absence of the AT receptor antagonist eprosartan. Additionally, to investigate a possible postjunctional facilitation, the effects of Ang II on alpha-adrenoceptor-mediated responses were studied using noradrenaline (NA). Lastly, the vasoconstrictor effects of Ang II were compared between HF rabbits and controls, by constructing concentration-response curves to Ang II. In control rabbits, Ang II 0.5 n caused an enhancement of stimulation-induced responses by a factor 3.2 +/- 0.5, 2.4 +/- 0.3, and 1.5 +/- 0.08, at 1, 2, and 4 Hz, respectively ( < 0.05 at all frequencies compared with vehicle). In rabbits with HF, the enhancement by Ang II (0.5 n ) amounted to a factor 2.1 +/- 0.2, 1.7 +/- 0.1, and 1.2 +/- 0.04, at 1, 2, and 4 Hz, respectively ( < 0.05 compared with vehicle at all frequencies). Accordingly, the enhancing effect of Ang II was more pronounced in the control group compared with rabbits with HF ( < 0.05 at each frequency). Eprosartan (1 nM -0.1 microM) could inhibit the facilitatory effects of Ang II in arteries from HF as well as from control rabbits. Contractile responses to exogenous NA (3 n -0.1 m ) were the same in HF rabbits and controls, and they were unaltered in the presence of Ang II 0.5 n Ang II (0.1 nM -1 microM) caused a concentration-dependent increase in contractile force, which was the same in HF rabbits and controls. From these findings it can be concluded that in rabbits with CHF as well as in control animals, Ang II facilitates the stimulation-induced vasoconstrictor responses via prejunctionally located AT receptors. The facilitating effect was decreased in vessels obtained from rabbits with CHF, whereas responses to exogenous Ang II were unchanged. These findings may be explained by downregulation or uncoupling of the prejunctional AT receptor.
No takes yet. Share an insight, caveat, or question.
Balt et al. (2003) studied Chronic heart failure. Angiotensin II vs. Vehicle / Control rabbits was evaluated on Enhancement of stimulation-induced vasoconstrictor responses at 1 Hz (p=<0.05). Angiotensin II facilitated stimulation-induced vasoconstrictor responses, but this enhancing effect was significantly decreased in mesenteric arteries from rabbits with chronic heart failure (P<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: